RPS6KA2 and melanoma: RSK activity is reported to be necessary and sufficient for cell migration, based on studies with RSK inhibitors SL0101, FMK, and BI-D1870 and constitutively active RSK1 and RSK2 in HeLa, MCF10a mammary epithelial, and WM35 melanoma cells (58, 61, 62).